Welcome to our dedicated page for Atrion news (Ticker: ATRI), a resource for investors and traders seeking the latest updates and insights on Atrion stock.
Atrion Corporation (ATRI) delivers innovative medical device solutions for modern healthcare through advanced engineering and regulatory-compliant products. This news hub provides investors and industry professionals with comprehensive updates on the company's developments in clinical technology and market operations.
Access real-time announcements including earnings reports, product innovations, and strategic partnerships. Our curated news collection offers insights into Atrion's role in advancing medical instrumentation while maintaining rigorous quality standards required by healthcare providers and regulatory bodies.
Key updates cover FDA clearances, clinical trial outcomes, and technology advancements critical to understanding the company's market position. Bookmark this page to monitor ATRI developments influencing the medical devices sector and investment considerations.
Atrion Corporation (NASDAQ: ATRI) declared a quarterly dividend of $2.15 per share on February 27, 2023. This dividend is set to be paid on March 31, 2023, to stockholders who are on record by the close of business on March 15, 2023. Atrion focuses on developing and manufacturing products for medical applications, enhancing its commitment to shareholder returns through consistent dividend payments. For further information, visit Atrion's website.
Atrion Corporation (NASDAQ: ATRI) reported strong fourth-quarter and full-year 2022 results. Q4 revenues reached $42.9 million, a 6% increase from $40.3 million in Q4 2021, with operating income rising 12% to $8.8 million. Full-year revenues grew 11% to $183.5 million, while net income increased to $35 million from $33.1 million. The diluted earnings per share for 2022 rose to $19.56 from $18.18. The company noted a slight decline in gross profit margin due to rising costs. Despite challenges, Atrion remains debt-free and is investing in future growth, including a $41 million ERP system and facility expansions.
Atrion Corporation (NASDAQ: ATRI) has declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock. The dividend is set to be paid on December 15, 2022, to stockholders of record as of the close of business on December 1, 2022. Atrion Corporation focuses on developing and manufacturing products for medical applications.
Atrion Corporation (NASDAQ: ATRI) reported third-quarter 2022 revenues of $44.6 million, up from $42.9 million in 2021, marking a 4% increase. Operating income rose to $9.6 million, while net income increased to $8.8 million, representing 7% and 8% growth respectively. Diluted earnings per share were $4.94, compared to $4.58 a year earlier. Despite challenges from Hurricane Ian, the company faced only delayed shipments costing $1.7 million. The CEO noted international recession concerns could shift customer orders to 2023, although gains are still expected.
Atrion Corporation (NASDAQ: ATRI) announced a succession plan appointing Cindy Ferguson as Vice President and Chief Financial Officer, effective March 4, 2023. This move follows the retirement of Jeffery Strickland, who has served in the role since 1997. Ferguson joined Atrion in June 2021 as the Company’s Controller, bringing 17 years of experience from Texas Instruments. The transition is designed to ensure stability and continuity in leadership. The Company specializes in developing medical products, with a focus on advancing future successes.
Atrion Corporation (Nasdaq ATRI) has announced an increase in its quarterly cash dividend from $1.95 to $2.15 per share. This increase reflects a commitment to enhance shareholder value. The dividend is payable on September 30, 2022, to stockholders of record by the close of business on September 15, 2022. Atrion specializes in developing and manufacturing products for medical applications.
FAQ
What is the current stock price of Atrion (ATRI)?
What is the market cap of Atrion (ATRI)?
